The vasostatin‐1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia‐driven endothelial cells and regulates tumor neovascularization
暂无分享,去创建一个
C. Doglioni | A. Corti | Lorenzo Veschini | E. Ferrero | L. Crippa | E. Dondossola | L. Veschini | Eleonora Dondossola
[1] A. Morganti,et al. Chromogranin A: a novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems , 2011, Journal of hypertension.
[2] S. Rong,et al. The Neuropeptide Catestatin Acts As a Novel Angiogenic Cytokine via a Basic Fibroblast Growth Factor–Dependent Mechanism , 2010, Circulation research.
[3] K. Helle. Regulatory Peptides from Chromogranin A and Secretogranin II , 2010, Cellular and Molecular Neurobiology.
[4] A. Corti. Chromogranin A and the Tumor Microenvironment , 2010, Cellular and Molecular Neurobiology.
[5] A. Malik,et al. Krüppel-Like Factor-4 Transcriptionally Regulates VE-Cadherin Expression and Endothelial Barrier Function , 2010, Circulation research.
[6] Dengwen Li,et al. CYLD regulates angiogenesis by mediating vascular endothelial cell migration. , 2010, Blood.
[7] R. Levi,et al. Vasostatin 1 activates eNOS in endothelial cells through a proteoglycan‐dependent mechanism , 2010, Journal of cellular biochemistry.
[8] M. Ferrarini,et al. Bortezomib induces autophagic death in proliferating human endothelial cells. , 2010, Experimental cell research.
[9] O. Alfieri,et al. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. , 2010, American journal of physiology. Heart and circulatory physiology.
[10] N. Mahapatra,et al. Chromogranin A: a novel susceptibility gene for essential hypertension , 2010, Cellular and Molecular Life Sciences.
[11] G. Semenza. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.
[12] Laura Fernández-Martín,et al. Adherens junctions connect stress fibres between adjacent endothelial cells , 2010, BMC Biology.
[13] S. Indraccolo,et al. The angiogenic switch: implications in the regulation of tumor dormancy. , 2009, Current molecular medicine.
[14] Frederik De Smet,et al. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way , 2009, Nature Reviews Clinical Oncology.
[15] Peter Carmeliet,et al. Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells , 2009, Journal of Molecular Medicine.
[16] Peter Carmeliet,et al. Mechanisms of Vessel Branching: Filopodia on Endothelial Tip Cells Lead the Way , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[17] V. Bautch. Endothelial Cells Form a Phalanx to Block Tumor Metastasis , 2009, Cell.
[18] Frederik De Smet,et al. Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization , 2009, Cell.
[19] Christian Fischer,et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.
[20] K. Helle,et al. The vasostatin‐I fragment of chromogranin A inhibits VEGF‐induced endothelial cell proliferation and migration , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] Dai Fukumura,et al. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. , 2007, Microvascular research.
[22] Dai Fukumura,et al. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.
[23] M. Ferrarini,et al. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. , 2007, Blood.
[24] R. Shoemaker,et al. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. , 2006, Blood.
[25] J. Pouysségur,et al. Transcriptional regulation of the Vascular Endothelial Growth Factor gene--a concert of activating factors. , 2005, Cardiovascular research.
[26] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[27] A. Villa,et al. Chromogranin A protects vessels against tumor necrosis factor α‐induced vascular leakage , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] G. Semenza. Angiogenesis in ischemic and neoplastic disorders. , 2003, Annual review of medicine.
[29] A. Corti,et al. Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. , 2002, Cancer research.
[30] R. Longhi,et al. Production and structure characterisation of recombinant chromogranin A N-terminal fragments (vasostatins) -- evidence of dimer-monomer equilibria. , 1997, European journal of biochemistry.
[31] W. Aird. Endothelium in health and disease. , 2008, Pharmacological reports : PR.
[32] A. Bikfalvi,et al. Tumor angiogenesis , 2020, Advances in cancer research.
[33] Richard P. Hill,et al. The hypoxic tumour microenvironment and metastatic progression , 2004, Clinical & Experimental Metastasis.